Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. “In 2025, venture capitalists are expected to prioritize ...
Additional clinical-stage programs, including a Phase 2/3 trial in advanced melanoma, underscore momentum across the company’s oncology pipeline Eikon Therapeutics, Inc., a late-stage clinical ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback